Table 1

Demographic, clinical and biological characteristics of the SSc population

Patients with lcSSc (n=50)Patients with dcSSc (n=23)All patients with SSc (n=73)P value*
Female (%)39 (78)9 (40)48 (65.8)
Age at onset, mean±SD years†48.7±13.249.9±14.549±13.5ns
Disease duration, mean±SD years†10.7±6.011.9±9.4711.5±8.6ns
RP (%)50 (100)23 (100)73 (100)ns
Digital ulcers (%)20 (40)7 (30.8)27 (37)0.02
mRSS, mean±SD5.9±5.524.6±12.711.1±11.6‡<0.0001
PAH (%)7 (14)1 (4.3)8 (11)§ns
Interstitial lung disease (%)11 (22)13 (56.5)24 (32.9)¶ns
Lung fibrosis (%)7 (14)1 (4.3)8 (11)¶ns
Renal crisis (%)1 (2)0 (0)1 (1.4)ns
Antinuclear autoantibody-positive50 (100)23 (100)73 (100)ns
Anticentromere antibody-positive25 (50)1 (4.34)26 (35.6)ns
Antitopoisomerase antibody-positive4 (8)11 (47.8)15 (20.5)ns
Anti-ARNIII polymerase antibody-positive1 (2)1 (4.34)2 (2.7)ns
Immunomodulatory agents44 (22)60.8 (14)49.3 (36)ns
  • Except where indicated otherwise, values are the number (%).

  • *lcSSc versus dcSSc.

  • †Age at onset of symptoms other than RP and disease duration since symptoms other than RP.

  • ‡Data were available for 34 patients.

  • §Data were available for 36 patients.

  • ¶Data were available for 35 patients.

  • dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous systemic sclerosis; mRSS, modified Rodnan skin thickness score; ns, not significant; PAH, pulmonary hypertension; RP, Raynaud’s phenomenon; SSc, systemic sclerosis.